Sanofi Labels Biosimilars 'Enormous Distraction'

French Player Has A Small Biosimilar Presence

 
• By Dean Rudge
  
Insulin pen
Sanofi exited diabetes research last year but kept hold of a biosimilar insulin aspart candidate • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products